Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusidic acid hydrophilic cream versus Fucidin cream for impetigo
2020-002219-24Phase 3Completed
- Sponsor
- Basic Pharma
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fusidic acid in impetigo (2 arms), sponsored by Basic Pharma. Primary endpoint: Clinical efficacy at day 7. Started Aug 2020; status: completed.
02
Drugs
fusidic acid
03
Conditions
impetigo
Beyond the preview
Go deeper on 2020-002219-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002219-24.